We are live on ! Find out more
RCM

RA Capital Management Portfolio holdings

AUM $9.44B
1-Year Est. Return 157.3%
This Fund
S&P 500
This Quarter Est. Return
+30%
1 Year Est. Return
+157.3%
3 Year Est. Return
+589.39%
5 Year Est. Return
+654.96%
10 Year Est. Return
+50,915.53%
AUM
$1.11B
AUM Growth
+$235M
Cap. Flow
+$32.1M
Cap. Flow %
2.9%
Top 10 Hldgs %
76.43%
Holding
31
New
9
Increased
4
Reduced
3
Closed
4

Top Buys

Rank Stock Value
1
KALA icon
KALA BIO
KALA
+$46.4M
2
KDMN
Kadmon Holdings, Inc.
KDMN
+$19M
3
IMMU
Immunomedics Inc
IMMU
+$14.7M
4
INSM icon
Insmed
INSM
+$13.8M
5
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$9.57M

Top Sells

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$33.9M
2
RDUS
Radius Health, Inc.
RDUS
+$22.5M
3
NGNE icon
Neurogene
NGNE
+$19.6M
4
BHVN
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
+$13.7M
5
AKBA icon
Akebia Therapeutics
AKBA
+$12M

Sector Composition

Rank Sector Weight
1 Healthcare 95.96%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ASND icon
1
Ascendis Pharma A/S
ASND
$16.6B
$202M 18.28%
5,580,690
– –
WVE icon
2
Wave Life Sciences
WVE
$1.11B
$154M 13.93%
7,088,651
– –
AVXS
3
DELISTED
AveXis, Inc. Common Stock
AVXS
$120M 10.82%
1,238,181
-71,865
-5% -$6.48M
BHVN
4
DELISTED
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
$74.7M 6.74%
1,997,278
-451,072
-18% -$13.7M
ACHN
5
DELISTED
Achillion Pharmaceuticals
ACHN
$61.2M 5.53%
13,633,220
– –
RXDX
6
DELISTED
Ignyta, Inc.
RXDX
$50.7M 4.58%
4,106,601
+89,611
+2% +$924K
GTHX
7
DELISTED
G1 Therapeutics, Inc. Common Stock
GTHX
$49.8M 4.5%
2,684,244
– –
KALA icon
8
KALA BIO
KALA
$13M
$48.3M 4.36%
+846
New +$46.4M
MYOV
9
DELISTED
Myovant Sciences Ltd.
MYOV
$43.8M 3.96%
2,830,455
+22,905
+0.8% +$279K
AVEO
10
DELISTED
AVEO Pharmaceuticals, Inc.
AVEO
$41.4M 3.74%
1,132,865
+289,307
+34% +$8.95M
BCRX icon
11
BioCryst Pharmaceuticals
BCRX
$2.42B
$36.6M 3.31%
6,984,692
+1,822,450
+35% +$9.33M
ZGNX
12
DELISTED
Zogenix, Inc.
ZGNX
$34.8M 3.14%
992,268
-482,420
-33% -$6.55M
INSM icon
13
Insmed
INSM
$22.3B
$22.6M 2.04%
+722,714
New +$13.8M
KDMN
14
DELISTED
Kadmon Holdings, Inc.
KDMN
$22.3M 2.02%
+6,666,666
New +$19M
ACOR
15
DELISTED
Acorda Therapeutics
ACOR
$21.3M 1.92%
7,502
– –
IMMU
16
DELISTED
Immunomedics Inc
IMMU
$20.7M 1.87%
+1,478,742
New +$14.7M
RARX
17
DELISTED
Ra Pharmaceuticals, Inc. Common Stock
RARX
$19.7M 1.78%
1,351,808
– –
SGMO
18
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
$18.8M 1.69%
1,250,000
– –
DRNA
19
DELISTED
Dicerna Pharmaceuticals, Inc.
DRNA
$14M 1.26%
2,428,571
– –
CMTA
20
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
$9.89M 0.89%
+585,403
New +$9.57M
TGTX icon
21
TG Therapeutics
TGTX
$8.14B
$8.29M 0.75%
700,000
– –
KRYS icon
22
Krystal Biotech
KRYS
$10.7B
$6.98M 0.63%
+700,000
New +$7.06M
VNDA icon
23
Vanda Pharmaceuticals
VNDA
$304M
$4.37M 0.39%
+243,971
New +$4.08M
KALV
24
DELISTED
KalVista Pharmaceuticals
KALV
$4.35M 0.39%
591,070
– –
CHMA
25
DELISTED
Chiasma, Inc. Common Stock
CHMA
$3.56M 0.32%
+1,396,400
New +$2.57M
1
2

Similar funds

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
SCM
SCS Capital Management Boston, Massachusetts $9.44B AUM 18.1% 1-Year Est. Return
SIM
SRS Investment Management New York $9.47B AUM 60.12% 1-Year Est. Return
NPT
National Philanthropic Trust Jenkintown, Pennsylvania $9.38B AUM 33.37% 1-Year Est. Return
AC
Allstate Corporation Northbrook, Illinois $9.35B AUM 16.13% 1-Year Est. Return
PVI
Partners Value Investments Hamilton, Bermuda $9.34B AUM 12.2% 1-Year Est. Return
WPL
WINDACRE PARTNERSHIP LLC Houston, Texas $9.34B AUM 17.41% 1-Year Est. Return
BAMF
BI Asset Management Fondsmaeglerselskab Kobenhavn, Denmark $9.55B AUM 31.94% 1-Year Est. Return

RA Capital Management's Q3 2017 Portfolio in Review

As of Q3 2017, RA Capital Management held 31 positions worth $1.11B, up 27% from $871M the previous quarter. Its ten largest holdings account for 76% of the portfolio.

RA Capital Management's Q3 2017 filing shows 9 new, 4 increased, 3 reduced and 4 closed positions. Its largest new stake was KALA BIO: 846 shares worth $48.3M. The largest sale was Esperion Therapeutics, an estimated $33.9M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 97% a quarter earlier.

  • RA Capital Management's largest Q3 2017 buy was KALA BIO: 846 shares worth $48.3M.
  • RA Capital Management added most to BioCryst Pharmaceuticals in Q3 2017, an estimated $9.33M increase.
  • RA Capital Management's biggest Q3 2017 reduction was Biohaven Pharmaceutical Holding Company Ltd., cutting an estimated $13.7M.
  • RA Capital Management fully exited Esperion Therapeutics in Q3 2017, selling an estimated $33.9M.
  • RA Capital Management's ten largest holdings make up 76% of its $1.11B portfolio in Q3 2017.
  • RA Capital Management opened 9 new positions and closed 4 in Q3 2017.
  • RA Capital Management's portfolio value rose 27% quarter-over-quarter to $1.11B.

Based on RA Capital Management's 13F filing for Q3 2017, filed 14 Nov 2017.